Intralesional epidermal growth factor for diabetic foot wounds: the first cases in Turkey

BACKGROUND: Intralesional recombinant epidermal growth factor (EGF) was produced in the Centre for Genetic Engineering and Biotechnology (CIGB), Cuba, in 1988 and licensed in 2006. Because it may accelerate wound healing, it is a potential new treatment option in patients with a diabetic foot wound...

Descripción completa

Detalles Bibliográficos
Autores principales: Ertugrul, Bulent M., Buke, Cagri, Ersoy, Ozlem Saylak, Ay, Bengisu, Demirez, Dilek Senen, Savk, Oner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2015
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534624/
https://www.ncbi.nlm.nih.gov/pubmed/26268583
http://dx.doi.org/10.3402/dfa.v6.28419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534624/
https://www.ncbi.nlm.nih.gov/pubmed/26268583
http://dx.doi.org/10.3402/dfa.v6.28419

Ejemplares similares